Drug Sponsors

Merck launches Biosimilars Clarified

Friday, October 14, 2016

Merck, known as MSD outside the U.S. and Canada, has launched Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community, designed to provide clear, concise and straightforward information about biosimilar medicines.

[Read More]

Helsinn Group launches Helsinn Investment Fund

Wednesday, October 12, 2016

Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, has introduced Helsinn Investment Fund, a fund focused on early-stage investment opportunities in areas of high unmet patient need. With an initial investment commitment of three years, followed by up to five years via follow-on rounds, the fund will have a total commitment of $50 million. The Helsinn Investment Fund is incorporated in Luxembourg and fully owned by the Helsinn Group.

[Read More]

ICU Medical to acquire the Hospira Infusion Systems Business from Pfizer for $1B

Thursday, October 6, 2016

ICU Medical will acquire all of Pfizer’s global infusion therapy business, Hospira Infusion Systems (HIS), for $1 billion in cash and stock. The Hospira Infusion Systems business includes IV pumps, solutions, and devices that, when combined with ICU Medical’s existing businesses, will create a leading pure-play infusion therapy company, with estimated pro forma combined revenues of approximately $1.45 billion based on trailing twelve month results as of June 2016.

[Read More]

ImmunoGen to cut workforce 17%

Tuesday, October 4, 2016

ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, has announced the completion of a strategic review of its operations. As a result of this initiative, the company will reduce its workforce by 17% and seek to partner its non-core B-cell lymphoma programs, creating a stronger organization focused on delivering innovative ADC therapies that meaningfully improve the lives of cancer patients.

[Read More]

Pfizer will not split

Tuesday, September 27, 2016

Pfizer has announced that, after an extensive evaluation, the company’s board of directors and executive leadership team have determined the company is best positioned to maximize future shareholder value creation in its current structure and will not pursue splitting Pfizer Innovative Health and Pfizer Essential Health into two separate, publicly traded companies at this time.

[Read More]